buserelin has been researched along with Local Neoplasm Recurrence in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (14.29) | 18.7374 |
| 1990's | 4 (57.14) | 18.2507 |
| 2000's | 2 (28.57) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cheung, P; Choo, R; Danjoux, C; Gardner, S; Loblaw, DA; Morton, G; Pearse, M; Szumacher, E | 2 |
| Cantwell, BM; Carmichael, J; Harris, AL; Lind, MJ; Millward, MJ; Proctor, M; Robinson, A; Simmons, D | 1 |
| Cirkel, U; Latussek, B; Ochs, H; Schneider, HP | 1 |
| Bianchi, S; Brioschi, D; Dorta, M; Fedele, L; Vercellini, P | 1 |
| Jacobi, GH | 1 |
| Claustrat, B; Forest, MG; Lahlou, N; Lejeune, H; Loras, B; Sassolas, G; Trouillas, J | 1 |
3 trial(s) available for buserelin and Local Neoplasm Recurrence
| Article | Year |
|---|---|
Efficacy of salvage radiotherapy plus 2-year androgen suppression for postradical prostatectomy patients with PSA relapse.
Topics: Aged; Androgen Antagonists; Buserelin; Drug Administration Schedule; Follow-Up Studies; Humans; Imidazolidines; Male; Middle Aged; Neoplasm Recurrence, Local; Pilot Projects; Prospective Studies; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Regression Analysis; Salvage Therapy; Survival Rate; Time Factors | 2009 |
A phase II trial of goserelin (Zoladex) in relapsed epithelial ovarian cancer.
Topics: Adult; Aged; Buserelin; Drug Evaluation; Female; Goserelin; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms | 1992 |
Treatment with GnRH agonists before myomectomy and the risk of short-term myoma recurrence.
Topics: Adult; Buserelin; Combined Modality Therapy; Female; Humans; Leiomyoma; Myometrium; Neoplasm Recurrence, Local; Randomized Controlled Trials as Topic; Uterine Neoplasms; Uterus | 1990 |
4 other study(ies) available for buserelin and Local Neoplasm Recurrence
| Article | Year |
|---|---|
Prospective study evaluating postoperative radiotherapy plus 2-year androgen suppression for post-radical prostatectomy patients with pathologic T3 disease and/or positive surgical margins.
Topics: Aged; Androgen Antagonists; Buserelin; Combined Modality Therapy; Humans; Imidazolidines; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm, Residual; Pilot Projects; Prospective Studies; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Regression Analysis; Survival Rate | 2009 |
[Value of the tumor markers CA 125, Ca 19-9, CA 15-3 and CEA in endometriosis].
Topics: Adult; Antigens, Tumor-Associated, Carbohydrate; Biomarkers, Tumor; Buserelin; Carcinoembryonic Antigen; Endometriosis; Female; Follow-Up Studies; Genital Neoplasms, Female; Humans; Neoplasm Recurrence, Local; Neoplasm Staging; Reoperation | 1991 |
LH-RH agonist monotherapy in patients with carcinoma of the prostate and reflections on the so-called total androgen blockade.
Topics: Antineoplastic Agents; Buserelin; Carcinoma; Gonadotropin-Releasing Hormone; Humans; Male; Neoplasm Recurrence, Local; Orchiectomy; Prostatic Neoplasms; Testosterone; Triptorelin Pamoate | 1990 |
Gonadotropin-releasing hormone agonists are unsuccessful in reducing tumoral gonadotropin secretion in two patients with gonadotropin-secreting pituitary adenomas.
Topics: Adenoma; Adult; Buserelin; Drug Evaluation; Follicle Stimulating Hormone; Gonadotropin-Releasing Hormone; Gonadotropins, Pituitary; Humans; Luteinizing Hormone; Male; Middle Aged; Neoplasm Recurrence, Local; Pituitary Neoplasms; Stimulation, Chemical; Testosterone; Time Factors; Triptorelin Pamoate | 1988 |